Transcriptomic Analysis Identifies the Effect of Beta-Blocking Agents on a Molecular Pathway of Contraction in the Heart and Predicts Response to Therapy

Bettina Heidecker, Michelle M. Kittleson, Edward K Kasper, Ilan S Wittstein, Hunter C. Champion, Stuart D. Russell, Kenneth L. Baughman, Joshua M. Hare

Research output: Contribution to journalReview article


Over the last decades, beta-blockers have been a key component of heart failure therapy. However, currently there is no method to identify patients who will benefit from beta-blocking therapy versus those who will be unresponsive or worsen. Furthermore, there is an unmet need to better understand molecular mechanisms through which heart failure therapies, such as beta-blockers, improve cardiac function, in order to design novel targeted therapies. Solving these issues is an important step towards personalized medicine. Here, we present a comprehensive transcriptomic analysis of molecular pathways that are affected by beta-blocking agents and a transcriptomic biomarker to predict therapy response.

Original languageEnglish (US)
Pages (from-to)107-121
Number of pages15
JournalJACC: Basic to Translational Science
Issue number3
Publication statusPublished - Apr 1 2016



  • beta-blocking agents
  • biomarker
  • gene expression
  • heart failure
  • transcriptomics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this